

19th December 2019

Our ref: FOI 03437

Dear

Thank you for your request for information.

Your Request

FOI Request re Number of Patients Treated

Please detail the number of Oncology patients treated by your Trust with the stated therapies, during the time period January 2019 to June 2019 inclusive.

	Total Number of Patients Treated:					
	Total Number of Patients Treated	Head & Neck Cancer	Adjuvant Melanoma	Metastatic Melanoma	Non-Small Cell Lung Cancer (NSCLC)	Renal Cell Carcinoma (RCC)
Pembrolizumab (Keytruda)						
Nivolumab (Opdivo)						
Ipilimumab (Yervoy)						
Dabrafenib (Tafinlar)						
Cabozantinib (Cabometyx)						
Sunitinib (Sutent)						

Chairman: Pearse Butler

Chief Executive: Kevin McGee (Interim)

RESEARCH MATTERS AND SAVES LIVES - TODAY'S RESEARCH IS TOMORROW'S CARE

Blackpool Teaching Hospitals is a Centre of Clinical and Research Excellence providing quality up to date care. We are actively involved in undertaking research to improve treatment of our patients. A member of the healthcare team may discuss current clinical trials with you.



Pazopanib (Votrient)						
Axitinib (Inlyta)						
Atezolizumab (Tecentriq)						
Sorafenib (Nexavar)						
Tivozanib (Fotivda)						
Lenvatinib (Lenvima)						
Cetuximab (Erbix)						
Everolimus (Afinitor)						
Vemurafenib (Zelboraf)						

Our Response

Our Trust does not record drug use with respect to clinical indication. To retrieve this information would require a manual trawl of patient case notes which would exceed 18 hours. This information is therefore exempt on the grounds of cost (Section 12(1)).

However, We are able to provide figures where the pharmacy has issued the listed products to either our Oncology Unit or McMillan Windmill Unit in the last 6 months.

	Total Number of Patients Treated
Pembrolizumab (Keytruda)	87
Nivolumab (Opdivo)	19
Ipilimumab (Yervoy)	1
Dabrafenib (Tafinlar)	0
Cabozantinib (Cabometyx)	11
Sunitinib (Sutent)	0
Pazopanib (Votrient)	16
Axitinib (Inlyta)	0
Atezolizumab (Tecentriq)	11
Sorafenib (Nexavar)	5
Tivozanib (Fotivda)	0
Lenvatinib (Lenvima)	0
Cetuximab (Erbix)	11
Everolimus (Afinitor)	4
Vemurafenib (Zelboraf)	0

The information in this response is provided under the terms of the Open Government Licence. Please see here for more information:

<http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>

The following link is a customer satisfaction survey if you would like to leave feedback:

<http://www.bfwh.nhs.uk/our-services/hospital-services/information-governance/foi-questionnaire/>

If you are dissatisfied with our response to your request for access to information you may ask us to carry out an internal review. You should do this by writing to:

The Information Governance Manager
Blackpool Teaching Hospitals NHS Foundation Trust
Blackpool Victoria Hospital
Whinney Heys Rd
Blackpool
FY3 8NR
Email: bfwh.pso@nhs.net

If you remain unhappy, you may make a complaint to the Information Commissioner's Office.

Yours Sincerely,

Stephen Connor
Freedom of Information Manager